Hepatitis B Virus and HIV Infection

Martín-Carbonero, Luz; Poveda, Eva

doi:10.1055/s-0032-1316466

Cited by 17 publications

(9 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The individual patient data were collected retrospectively, resulting in partially incomplete information on several key variables such as HIV-coinfection. This is of importance as the epidemiological and clinical determinants of HBV infection are linked to the presence of HIV-coinfection [ 31 ]. It also underlines the importance of conducting prospective, large cohort studies dedicated to the study of HBV infection.…”

Section: Discussionmentioning

confidence: 99%

Molecular epidemiology of hepatitis B virus infection in Switzerland: a retrospective cohort study

et al. 2015

View full text Add to dashboard Cite

BackgroundChronic hepatitis B virus (HBV) infection affects up to 7 % of the European population. Specific HBV genotypes are associated with rapid progression to end-stage liver disease and sub-optimal interferon treatment responses. Although the geographic distribution of HBV genotypes differs between regions, it has not been studied in Switzerland, which lies at the crossroads of Europe.MethodsIn a retrospective analysis of 465 HBV samples collected between 2002 and 2013, we evaluated the HBV genotype distribution and phylogenetic determinants, as well as the prevalence of serological evidence of hepatitis delta, hepatitis C and HIV infections in Switzerland. Baseline characteristics of patients were compared across their region of origin using Fisher’s exact test and ANOVA, and risk factors for HBeAg positivity were assessed using logistic regression.ResultsThe Swiss native population represented 15.7 % of HBV-infected patients living in Switzerland. In the overall population, genotype D was most prevalent (58.3 %), whereas genotype A (58.9 %) was the predominant genotype among the Swiss native population. The prevalence of patients with anti-HDV antibodies was 4.4 %. Patients of Swiss origin were most likely to be HBeAg-positive (38.1 %). HBV genotypes of patients living in Switzerland but sharing the same original region of origin were consistent with their place of birth.ConclusionsThe molecular epidemiology of HBV infection in Switzerland is driven by migration patterns and not by the genotype distribution of the native population. The prevalence of positive anti-HDV antibodies in our cohort was very low.Electronic supplementary materialThe online version of this article (doi:10.1186/s12879-015-1234-z) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular epidemiology of hepatitis B virus infection in Switzerland: a retrospective cohort study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Both the risk of HBV infection and that of chronicity are increased in HIV‐seropositive persons . Chronic HBV infection is found in 5–10% of HIV‐positive persons worldwide and co‐infected persons show increased rates of progression to cirrhosis and liver cancer and a higher mortality than persons with either infection alone .…”

Section: Hepatitis Bmentioning

confidence: 99%

British HIV Association Guidelines on the Use of Vaccines in HIV‐Positive Adults 2015

et al. 2016

View full text Add to dashboard Cite

“…Preliminary data indicate that the development of multiple lamivudine associated mutations may even reduce the efficacy of tenofovir therapy [ 4 ]. However, we have a good number of patients who are on lamivudine therapy with excellent viral response who need a continuous followup to observe the development of LAM resistance.…”

Section: Introductionmentioning

confidence: 99%

High Dose of Lamivudine and Resistance in Patients with Chronic Hepatitis B

Wani

Kaabi

Sharma

et al. 2014

Hepatitis Research and Treatment

View full text Add to dashboard Cite

Background. Lamivudine is the most affordable drug used for chronic hepatitis B and has a high safety profile. With the daily dose of 100 mg there is progressive appearance of resistance to lamivudine therapy. In our study we used 150 mg of lamivudine daily as a standard dose which warrants further exploration for the efficacy of the drug. Aims of the Study. To assess the efficacy of lamivudine 150 mg daily on resistance in patients with chronic hepatitis B. Methods. This retrospective study consists of 53 patients with chronic hepatitis B treated with 150 mg of lamivudine daily. The biochemical and virological response to the treatment were recorded at a 1-year and 2-, 3-, 4-, and 5-year period and time of emergence of resistance to the treatment was noted. Results. The mean age of the patients was 54 years with 80% being males. The resistance to lamivudine 150 mg daily at 1 year and 2, 3, and 5 years was 12.5%, 22.5%, 37.5%, and 60%, respectively, which is much less compared to the standard dose of 100 mg of lamivudine. Conclusions. Lamivudine is safe and a higher dose of 150 mg daily delays the resistance in patients with chronic hepatitis B.

show abstract

Hepatitis B Virus and HIV Infection

Cited by 17 publications

References 51 publications

Molecular epidemiology of hepatitis B virus infection in Switzerland: a retrospective cohort study

Molecular epidemiology of hepatitis B virus infection in Switzerland: a retrospective cohort study

British HIV Association Guidelines on the Use of Vaccines in HIV‐Positive Adults 2015

High Dose of Lamivudine and Resistance in Patients with Chronic Hepatitis B

Contact Info

Product

Resources

About